November 5, 2019




U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549


Re:CNS Pharmaceuticals, Inc.
RegistrationStatement on Form S-1
RegistrationNo. 333-232443



Ladies and Gentlemen:


Pursuant to Rule 461 of the Securities Act of 1933, as amended, CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:30 P.M. (Eastern Time) on November 7, 2019, or as soon thereafter as possible on such date.




  Very truly yours,
  CNS Pharmaceuticals, Inc.
  By:    /s/ John Climaco              
    Name: John Climaco
    Title: Chief Executive Officer